Nefazodone (Serzone)
What studies of Nefazodone (Serzone) found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 4 of 5 findings are C.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Nefazodone (Serzone) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Nefazodone (Serzone) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Fatigue2 studies · 20 people took Nefazodone (Serzone) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (20 in all); not all results were tested against chance.
Studies with no comparison group2 studies · 20 people with results
Fatigue improved.
The evidence is very uncertain about the effect of nefazodone (Serzone) on fatigue in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (20 in all)
- Not all results were tested against chance
See the 2 studies
-
Nefazodone for patients with chronic fatigue syndrome. (1999)
- People in the study
- 10 in the study
- Dose
- 370 mg (range = 200–800 mg/day), commencing at 50 mg at night for three nights followed by 50 mg twice daily or 100 mg at night for 1week
- Outcome
- fatigue: at least some improvement
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
Treatment of chronic fatigue syndrome with nefazodone. (1999)
- People in the study
- 10 in the study
- Dose
- 370 mg/day (range == 200–800 mg), strong preference for nocturnal dosing
- Outcome
- at least some improvement in the key symptom of fatigue
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety2 studies · 20 people took Nefazodone (Serzone) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (20 in all); not all results were tested against chance.
Studies with no comparison group2 studies · 20 people with results
Low mood or anxiety improved.
The evidence is very uncertain about the effect of nefazodone (Serzone) on low mood or anxiety in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (20 in all)
- Not all results were tested against chance
See the 2 studies
-
Nefazodone for patients with chronic fatigue syndrome. (1999)
- People in the study
- 10 in the study
- Dose
- 370 mg (range = 200–800 mg/day), commencing at 50 mg at night for three nights followed by 50 mg twice daily or 100 mg at night for 1week
- Outcome
- mood: moderately or markedly improved
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
Treatment of chronic fatigue syndrome with nefazodone. (1999)
- People in the study
- 10 in the study
- Dose
- 370 mg/day (range == 200–800 mg), strong preference for nocturnal dosing
- Outcome
- mood
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep2 studies · 20 people took Nefazodone (Serzone) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (20 in all); not all results were tested against chance.
Studies with no comparison group2 studies · 20 people with results
Sleep improved.
The evidence is very uncertain about the effect of nefazodone (Serzone) on sleep in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (20 in all)
- Not all results were tested against chance
See the 2 studies
-
Nefazodone for patients with chronic fatigue syndrome. (1999)
- People in the study
- 10 in the study
- Dose
- 370 mg (range = 200–800 mg/day), commencing at 50 mg at night for three nights followed by 50 mg twice daily or 100 mg at night for 1week
- Outcome
- sleep disturbance: moderately or markedly improved
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
Treatment of chronic fatigue syndrome with nefazodone. (1999)
- People in the study
- 10 in the study
- Dose
- 370 mg/day (range == 200–800 mg), strong preference for nocturnal dosing
- Outcome
- sleep disturbance
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning2 studies · 20 people took Nefazodone (Serzone) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (20 in all); not all results were tested against chance.
Studies with no comparison group2 studies · 20 people with results
Daily functioning improved.
The evidence is very uncertain about the effect of nefazodone (Serzone) on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (20 in all)
- Not all results were tested against chance
See the 2 studies
-
Nefazodone for patients with chronic fatigue syndrome. (1999)
- People in the study
- 10 in the study
- Dose
- 370 mg (range = 200–800 mg/day), commencing at 50 mg at night for three nights followed by 50 mg twice daily or 100 mg at night for 1week
- Outcome
- overall functional outcome: at least moderate improvement and return to work or previous role function
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
Treatment of chronic fatigue syndrome with nefazodone. (1999)
- People in the study
- 10 in the study
- Dose
- 370 mg/day (range == 200–800 mg), strong preference for nocturnal dosing
- Outcome
- overall functional outcome
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 10 people took Nefazodone (Serzone) Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (10 in all).
Studies with no comparison group10 in the study · The mean duration of treatment for all patients was 20.8 (range = 4–40) weeks · 370 mg (range = 200–800 mg/day), commencing at 50 mg at night for three nights followed by 50 mg twice daily or 100 mg at night for 1week
No clear change in overall symptoms.
The evidence is very uncertain about the effect of nefazodone (Serzone) on overall symptoms in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (10 in all)
See the 1 study
-
Nefazodone for patients with chronic fatigue syndrome. (1999)
- People in the study
- 10 in the study
- Dose
- 370 mg (range = 200–800 mg/day), commencing at 50 mg at night for three nights followed by 50 mg twice daily or 100 mg at night for 1week
- Outcome
- no improvement on any assessment parameters
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
Stopping because of side effects1 study
One patient discontinued therapy after 4 weeks due to increased somnolence (200 mg/day
Nefazodone for patients with chronic fatigue syndrome. (1999)
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
50 to 200 mg at the start
- 2Raise
Raised step by step in 2 of 2 studies
- 3Top dose
Most often 800 mg (2 of 2 studies)
Doses across 2 studies
50 to 800 mg.
Each study’s dose, as printed
- 370 mg (range = 200–800 mg/day), commencing at 50 mg at night for three nights followed by 50 mg twice daily or 100 mg at night for 1week Nefazodone for patients with chronic fatigue syndrome. (1999)
- 370 mg/day (range == 200–800 mg), strong preference for nocturnal dosing Treatment of chronic fatigue syndrome with nefazodone. (1999)
All papers
- Nefazodone for patients with chronic fatigue syndrome.1999 · no comparison group · 10 in the study
Summary
This was an open evaluation of nefazodone in 10 patients with chronic fatigue syndrome (CFS) presenting for assessment by a specialist psychiatrist; patients were frequently referred to this specialist psychiatrist practice for evaluation of chronic fatigue states. Five males and five female patients with a mean age of 47.5 ± 15 (range = 28–82) years were treated with nefazodone for at least 6 weeks. Nefazodone was introduced very slowly, typically commencing at 50 mg at night for three nights followed by 50 mg twice daily or 100 mg at night for 1 week. The mean dose was 370 mg (range = 200–800 mg/day), with a strong preference for nocturnal dosing. The mean duration of treatment for all patients was 20.8 (range = 4–40) weeks. Outcome was assessed after 6 weeks by clinical global ratings. There was no comparison group. Of the 10 patients, eight (80%) reported at least some improvement in the key symptom of fatigue, with four (40%) reporting moderate or marked improvement. Sleep disturbance was improved moderately or markedly in seven (70%), mood in eight (80%), and five (50%) achieved at least a moderate improvement in overall functional outcome and were able to return to work or their previous level of role function. Two patients showed no improvement on any assessment parameters; one patient discontinued after 4 weeks with increased somnolence (200 mg/day).
- Treatment of chronic fatigue syndrome with nefazodone.1999 · no comparison group · 10 in the study
Summary
This study examined nefazodone in 10 patients with chronic fatigue syndrome who were assessed by a specialist psychiatrist. Patients treated in this service were also advised to use behavioural and sleep-wake cycle strategies. Nefazodone was given at a mean dose of 370 mg/day (range 200–800 mg), with a strong preference for nocturnal dosing. The paper reports no comparison group and does not state treatment duration or follow-up. Outcomes were improvements reported for the patients. Eight of the 10 patients (80%) reported at least some improvement in the key symptom of fatigue, and four (40%) reported moderate or marked symptom relief. Sleep disturbance was moderately or markedly improved in seven (70%), and mood in eight (80%). Five patients (50%) achieved at least a moderate improvement in overall functional outcome and were able to return to work or their previous level of role function. Harms and withdrawals were not reported. The authors conclude that nefazodone appears worthy of further systematic investigation in patients with CFS, and that given its effects on sleep, mood and anxiety symptoms it may have particular advantages in this disorder. They do not state limitations.
- A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.2016 · systematic review
Summary
This systematic review examined drug therapies for chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME). Ovid MEDLINE, EMBASE, and PubMed were searched from the beginning of their archives to March 2016. The review included 26 randomized, placebo-controlled trials that met its criteria; these trials tested 20 drug therapies. The review reports effectiveness by categories from not effective to highly effective and says no universal pharmaceutical treatment can be recommended. Hydrocortisone findings were conflicting: across studies it was reported as mildly effective, slightly effective, not effective, and moderately effective; in one study the well-being improvement was not significant, and Blockmans et al found no clinical improvement. Rituximab was reported to produce a significant and lasting improvement, but the review states it is premature to conclude a lasting improvement in primary assessed domains; primary end points were evaluated for 3 months and secondary end points up to 12 months. For intravenous immunoglobulin, Rowe reported headache, fatigue, and difficulty concentrating significantly worse in the intervention group after the first infusion, with no differences after the third and final infusion. The review states no pharmaceutical therapy resulted in severe adverse events. It notes nefazodone was discontinued in 2004 after patients developed hepatic and visual disorders. Forsyth et al and Young each had N = 26; Young lacked male participants in the intervention cohort. The authors state that no clear recommended pharmaceutical therapy for CFS/ME exists and call for standardized diagnostic criteria and outcome measurements.